SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
 
SCHEDULE TO
Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of
the Securities Exchange Act of 1934

(Amendment No. 4)

SCIELE PHARMA, INC.
(Name of Subject Company)
 
TALL BRIDGE, INC.
SHIONOGI & CO., LTD.
(Names of Filing Persons — Offeror)
 
Common Stock, Par Value $0.001 Per Share
 (Title of Class of Securities)
________________
 
808627103
(Cusip Number of Class of Securities)

Isao Teshirogi
Shionogi & Co., Ltd.
1-8 Doshomachi 3-chome
Chuo-ku, Osaka, 541-0045, Japan
Telephone: +81 6 6202-2161
(Name, Address and Telephone Number of Person Authorized to Receive Notices
and Communications on Behalf of Filing Persons)

Copies to:

Theodore A. Paradise
Michael Davis
Davis Polk & Wardwell
450 Lexington Avenue
New York, New York 10017
Telephone: (212) 450-4000


£
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

R
third-party tender offer subject to Rule 14d-1.

£
issuer tender offer subject to Rule 13e-4.

£
going-private transaction subject to Rule 13e-3.

£
amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer.   þ  
 
 


 
 
This Amendment No. 4 (“ Amendment No. 4 ”) amends and supplements the Tender Offer Statement on Schedule TO (as previously amended, the “ Schedule TO ”) originally filed on September 8, 2008 by Shionogi & Co., Ltd., a joint stock corporation ( kabushiki kaisha ) incorporated under the laws of Japan (“ Shionogi ”), and Tall Bridge, Inc., a Delaware corporation (“ Purchaser ”) and an indirect wholly owned subsidiary of Shionogi, relating to the offer by Purchaser to purchase all outstanding shares of common stock, par value $0.001 per share (the “ Shares ”), of Sciele Pharma, Inc., a Delaware corporation (“ Sciele ”), at $31.00 per Share, net to the seller in cash, without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase dated September 8, 2008 (the “ Offer to Purchase ”) and in the related Letter of Transmittal (which, together with any amendments or supplements thereto, collectively constitute the “ Offer ”).
 
All capitalized terms used in this Amendment No. 4 without definition have the meanings ascribed to them in the Schedule TO.
 
The items of the Schedule TO set forth below are hereby amended and supplemented as follows:

Item 11. Additional Information

Item 11 of the Schedule TO is hereby amended and supplemented by adding the following:

“On October 9, 2008, Shionogi and Sciele issued a joint press release announcing the completion of the Offer. The Subsequent Offering Period of the Offer expired at 5:00 p.m., New York City time, on Wednesday, October 8, 2008. According to the Depositary, as of the expiration of the Subsequent Offering Period, a total of approximately 29,758,788 Shares were validly tendered in the offering period of the Offer, which represent approximately 92.0% of all outstanding Shares. Purchaser has accepted for payment all Shares that were validly tendered during the offering period, and payment for such Shares has or will be made promptly, in accordance with the terms of the Offer. The full text of a joint press release issued by Shionogi and Sciele announcing the completion of the Offer is filed as Exhibit (a)(9) hereto and is incorporated herein by reference.

The acquisition of Sciele is expected to be completed as of 5:00 p.m. Eastern Daylight Time on October 9, 2008, upon the effectiveness of the Merger under the short-form merger provisions of the DGCL without prior notice to, or any action by, any other Sciele stockholder. At the Merger Effective Time, each outstanding Share (other than any Shares in respect of which appraisal rights are validly exercised under the DGCL and any Shares owned by Sciele, Shionogi or any of their subsidiaries) will be converted into the right to receive the same $31.00 in cash per Share, without interest, that was paid in the Offer.  As a result of the Merger, Sciele will become an indirect wholly owned subsidiary of Shionogi.”

Item 12. Exhibits.

Item 12 of the Schedule TO is hereby amended and supplemented by adding the following exhibit:

 
“(a)( 9
Joint press release issued by Shionogi and Sciele dated October 9, 2008.”


 
2

 

 
SIGNATURES
 
After due inquiry and to the best knowledge and belief of the undersigned, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: October 9, 2008
 
 
TALL BRIDGE, INC.
 
       
 
By:
/s/ Sachio Tokaji  
    Name: Sachio Tokaji  
   
Title:   Treasurer & Director
 
       
 
 
SHIONOGI & CO., LTD.
 
       
 
By:
/s/ Isao Teshirogi  
    Name: Isao Teshirogi  
   
Title:   President & Representative Director
 
       
 

 
 
 

 
 
 


 
EXHIBIT INDEX
 

Exhibit No.
 
Description
(a)(9)
 
Joint press release issued by Shionogi and Sciele dated October 9, 2008 .

 
 
 
 

Sciele Pharma (MM) (NASDAQ:SCRX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Sciele Pharma (MM).
Sciele Pharma (MM) (NASDAQ:SCRX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Sciele Pharma (MM).